Lantern and AccessHope surveyed 240 HR and benefits decision-makers at self-funded employers to learn whether their strategies align with what truly lowers costs and delivers better results for patients. See what we found and where your strategy stands.
What's inside:
Why cancer is losing the attention battle it should be winning, even as it dominates cost
Where the gap shows up between what employers believe about expert care and what they offer
What employers should know about driving engagement in a comprehensive program
Download Now
Key Findings
94% believe early expert intervention improves outcomes
But only 6% use external oncology experts to review high-cost decisions
Cancer is the top unmanaged risk benefits leaders see coming
But have they built a strategy to match the risk they see coming?
94% of respondents say GLP-1s get equal or more executive attention than cancer
The costliest condition gets the least executive airtime.
